| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957113 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US8022106 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US8273795 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US8487005 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US7947739 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US8791160 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US8809394 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
| US9060939 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(10 months from now) | |
Lysteda is owned by Amring Pharms.
Lysteda contains Tranexamic Acid.
Lysteda has a total of 8 drug patents out of which 0 drug patents have expired.
Lysteda was authorised for market use on 13 November, 2009.
Lysteda is available in tablet;oral dosage forms.
Lysteda can be used as treatment of cyclic heavy menstrual bleeding.
The generics of Lysteda are possible to be released after 04 March, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 13, 2012 |
Drugs and Companies using TRANEXAMIC ACID ingredient
Market Authorisation Date: 13 November, 2009
Treatment: Treatment of cyclic heavy menstrual bleeding
Dosage: TABLET;ORAL
How can I launch a generic of LYSTEDA before it's drug patent expiration?
More Information on Dosage
LYSTEDA family patents
